Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cannabidiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 5/20 | 1.00 |
| ▸ | CNR2 | P34972 | 9/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE9A | O76083 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LDHA | P00338 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cannabidiol SCHEMBL16224872 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL1644403 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL119679 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL23934764 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL2229837 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL23460334 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL20201772 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL2799993 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL20930113 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL16212393 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3923917-B1 | PROCESS FOR THE SYNTHESIS OF CANNABIDIOL AND INTERMEDIATES THEREOF | COUNCIL OF SCIENT & INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATIO (IN) | 2026-03-04 | — | — | EP | claimed |
| US-12390418-B2 | Biphasic compositions comprising one or both of carbonate and phosphate | Natural Extraction Systems, LLC (US) | 2025-08-19 | — | — | US | claimed |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | INMED PHARMACEUTICALS INC. (CA) | 2025-07-15 | — | — | US | claimed |
| US-12234203-B2 | Process for the synthesis of cannabidiol and intermediates thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2025-02-25 | — | — | US | claimed |
| US-20250009655-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC | 2025-01-09 | — | — | US | claimed |
| US-20240269153-A1 | BIOACTIVE BIPHASIC COMPOSITIONS | NATURAL EXTRACTION SYS LLC (US) | 2024-08-15 | — | — | US | claimed |
| US-12023363-B2 | Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression | KLELE LUKE (US) | 2024-07-02 | — | — | US | claimed |
| US-12012373-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2024-06-18 | — | — | US | claimed |
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2024-04-25 | — | — | US | claimed |
| US-11860174-B2 | Anti-cannabidiol antibody and uses thereof | Bomi LLC (US) | 2024-01-02 | — | — | US | claimed |
| EP-3452036-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | Inmed Pharmaceuticals Inc. (CA) | 2019-03-13 | — | — | EP | claimed |
| WO-2017190249-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2017-11-09 | — | — | WO | claimed |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2016-03-17 | — | — | US | claimed |
| US-9186386-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-11-17 | — | — | US | claimed |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | claimed |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-09 | — | — | US | claimed |
| EP-2424568-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | University Of Kentucky Research Foundation (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010126501-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-04 | — | — | WO | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234203-B2 | Process for the synthesis of cannabidiol and intermediates thereof | CNR2, CNR1, MCCC2 | CNR1 2/4885CNR2 1/4885OPRM1 275/4885 |
| US-11860174-B2 | Anti-cannabidiol antibody and uses thereof | CNR2, CNR1, MAG | CNR1 2/4885CNR2 1/4885OPRM1 415/4885 |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | CNR2, CNR1, LCAT | CNR1 2/4885CNR2 1/4885OPRM1 268/4885 |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | CNR1 2/4885CNR2 1/4885OPRM1 111/4885 |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | CNR1 2/4885CNR2 1/4885OPRM1 111/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | CNR1 2/4885CNR2 1/4885OPRM1 240/4885 |
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR1, CNR2, OPRD1 | CNR1 1/4885CNR2 2/4885OPRM1 5/4885 |
| US-12012373-B2 | Cannabinoid derivatives | CNR2, CNR1, HTR2A | CNR1 2/4885CNR2 1/4885OPRM1 9/4885 |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885OPRM1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.